Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	2,439	1,874	2,099	1,803	693	36
Market Cap Growth	38.13%	-10.71%	16.42%	160.11%	1827.20%	5.39%
Enterprise Value	1,618	1,453	1,798	1,398	502	-25
PE Ratio	-	-13.25	-18.69	-25.57	-11.60	-0.71
PS Ratio	401.74	272.34	890.64	387.68	93.45	10.07
PB Ratio	2.91	4.37	6.44	4.30	3.31	0.38
P/FCF Ratio	-19.40	-17.18	-19.90	-29.02	-16.54	-0.76
P/OCF Ratio	-19.66	-17.47	-20.24	-29.60	-17.16	-0.77
EV/Sales Ratio	266.41	211.16	762.97	300.56	67.71	-6.93
EV/EBITDA Ratio	-10.75	-10.50	-16.43	-20.66	-8.81	0.54
EV/EBIT Ratio	-10.52	-10.28	-16.01	-19.76	-8.24	0.49
EV/FCF Ratio	-12.61	-13.32	-17.05	-22.50	-11.99	0.53
Debt / Equity Ratio	0.00	0.01	0.01	0.01	0.02	0.04
Debt / EBITDA Ratio	-0.01	-0.02	-0.04	-0.04	-0.06	-0.08
Debt / FCF Ratio	-0.02	-0.02	-0.04	-0.05	-0.08	-0.08
Quick Ratio	31.44	13.69	16.41	24.71	13.81	5.62
Current Ratio	31.77	13.87	17.07	24.86	13.93	5.73
Asset Turnover	0.01	0.02	0.01	0.01	0.03	0.03
Return on Equity (ROE)	-32.30%	-45.00%	-31.30%	-22.90%	-31.40%	-48.70%
Return on Assets (ROA)	-30.30%	-41.30%	-29.00%	-21.20%	-27.60%	-37.40%
Return on Capital (ROIC)	-19.35%	-35.80%	-36.97%	-17.19%	-31.75%	-57.66%
Earnings Yield	-5.94%	-7.54%	-5.35%	-3.91%	-8.62%	-141.45%
FCF Yield	-4.96%	-5.82%	-5.03%	-3.45%	-6.04%	-131.01%
Buyback Yield / Dilution	-24.69%	-3.33%	-9.37%	-44.64%	-104.32%	-38.93%
Total Shareholder Return	-24.69%	-3.33%	-9.37%	-44.64%	-104.32%	-38.93%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).